» Articles » PMID: 15942703

Inclusion Body Myositis. Clinical Features and Clinical Course of the Disease in 64 Patients

Abstract

The clinical features of inclusion body myositis (IBM) were of minor importance in the design of consensus diagnostic criteria, mainly because of controversial views on the specificity of signs and symptoms, although some authors reported "typical" signs. To re-assess the clinical spectrum of IBM, a single investigator using a standard protocol studied a cohort of 64 patients cross-sectionally. Symptom onset was before the age of 50 years in 20% of cases. Only a few patients (14 %) started with weakness other than that of quadriceps, finger flexor or pharyngeal muscles. The sequence of power loss was erratic, but onset of symptoms with quadriceps weakness predicted an earlier onset of dysphagia in older patients (> or = 56 years) compared with younger ones (< 56 years) (p = 0.02). Despite widespread weakness patients had favourable scores on three commonly used function scales and they kept their employment. Complete wheel-chair dependency was rare (3 %). A dominant characteristic was the anatomical distribution of afflicted muscles: ventral extremity muscle groups were more affected than dorsal muscle groups and girdle muscles were least affected, the latter preserving postural stability. Ankylosis, especially in extension of the fingers,was frequently present. Together with the sparing of intrinsic hand muscles it was helpful in the preservation of many skillful movements. IBM has a unique distribution of muscle weakness. Ankylotic contractures are common. We feel that their joint impact on daily functioning is characteristic for the disease.

Citing Articles

Cost of illness in inclusion body myositis: results from a cross-sectional study in Germany.

Senn K, Thiele S, Kummer K, Walter M, Nagels K Orphanet J Rare Dis. 2023; 18(1):337.

PMID: 37880781 PMC: 10601274. DOI: 10.1186/s13023-023-02902-3.


Face to Face: deciphering facial involvement in inclusion body myositis.

Fortanier E, Delmont E, Kouton L, Corazza G, Grapperon A, Verschueren A J Neurol. 2023; 271(1):410-418.

PMID: 37740740 DOI: 10.1007/s00415-023-11986-7.


Patient-Reported Health-Related Quality of Life, Anxiety and Depression in Patients with Inclusion Body Myositis: A Register-Based Cross-Sectional Study in Germany.

Senn K, Thiele S, Kummer K, Walter M, Nagels K J Clin Med. 2023; 12(15).

PMID: 37568453 PMC: 10420164. DOI: 10.3390/jcm12155051.


Exploring challenges in the management and treatment of inclusion body myositis.

Skolka M, Naddaf E Curr Opin Rheumatol. 2023; 35(6):404-413.

PMID: 37503813 PMC: 10552844. DOI: 10.1097/BOR.0000000000000958.


Inclusion body myositis with early onset: a population-based study.

Lindgren U, Hedberg-Oldfors C, Pullerits R, Lindberg C, Oldfors A J Neurol. 2023; 270(11):5483-5492.

PMID: 37498322 PMC: 10576680. DOI: 10.1007/s00415-023-11878-w.


References
1.
Griggs R, Askanas V, DiMauro S, Engel A, Karpati G, Mendell J . Inclusion body myositis and myopathies. Ann Neurol. 1995; 38(5):705-13. DOI: 10.1002/ana.410380504. View

2.
Lotz B, Engel A, Nishino H, Stevens J, Litchy W . Inclusion body myositis. Observations in 40 patients. Brain. 1989; 112 ( Pt 3):727-47. DOI: 10.1093/brain/112.3.727. View

3.
Felice K, Relva G, Conway S . Further observations on forearm flexor weakness in inclusion body myositis. Muscle Nerve. 1998; 21(5):659-61. DOI: 10.1002/(sici)1097-4598(199805)21:5<659::aid-mus17>3.0.co;2-q. View

4.
Sayers M, Chou S, Calabrese L . Inclusion body myositis: analysis of 32 cases. J Rheumatol. 1992; 19(9):1385-9. View

5.
Peng A, Koffman B, Malley J, Dalakas M . Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology. 2000; 55(2):296-8. DOI: 10.1212/wnl.55.2.296. View